The community executive considers that the Spanish Hipra vaccine adds “one more option” that complements the community vaccine portfolio
- vaccination The reduction of antibodies six months after being vaccinated against Covid-19 supports the use of a booster dose
- Coronavirus Hipra highlights the protection of its vaccine against Covid in the face of the autumn booster
The European Commission announced this Tuesday the signing of a contract for the acquisition next fall of 250 million doses of the vaccine against Covid-19 developed by the Spanish company Hipra, whose drug is still pending approval by the European Medicines Agency (EMA).
As reported by the EC in a statement, 14 Member States and countries participate in the acquisition, which can request up to 250 million doses. “Given the new increase in cases in Europe, this agreement will make the Hipra vaccine available to participating countries, as soon as the vaccine has received a positive evaluation by the European Medicines Agency,” the Commission said.
The Community Executive appreciates that the HIPRA protein vaccine adds “one more option” that complements the community vaccine portfolio, declared the Commissioner for Health and Food Safety, Stella Kyriakides. The acquisition contract with Hipra, based in Gerona, is added to those signed by Brussels with the pharmaceutical companies AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNtech-Pfizer, Moderna, Novavax, and Valneva.
According to the Commission, some 4.2 billion doses have been obtained under the EU Vaccine Strategy and the participating countries could decide to donate the vaccines to low- and middle-income countries or redirect them to other European countries.
“Faced with the increase in Covid-19 infections in Europe, we have to ensure maximum preparation for the autumn and winter months,” Kyriakides said. Hipra’s vaccine against Covid-19 is based on two structurally similar recombinant proteinsone corresponding to the alpha variant and the other to the beta variant, which join together to form a single structure called a dimer, and which is accompanied by an adjuvant that increases the immune response.
One of its advantages is that can be adapted to variants, according to the pharmacist. The prophylaxis, which is currently under review by the EMA, is being developed as a booster dose in previously immunized people aged 16 and over and if it receives marketing authorization, participating countries will be able to purchase it through the current contract. .